New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePal-GHK vs Chonluten

Pal-GHK vs Chonluten

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Pal-GHK
Anti-Aging & Longevity
Chonluten
Summary
Pal-GHK is the palmitoylated form of the GHK tripeptide without a copper ion. By conjugating palmitic acid to glycine-histidine-lysine, skin penetration is substantially enhanced, enabling deeper dermal collagen stimulation. It is commonly paired with Pal-GHK-Cu or GHK-Cu in anti-aging formulations.
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
Half-Life
Extended (lipid depot in stratum corneum)
Short (minutes for the peptide); sustained gene-regulatory effects
Admin Route
Topical
SubQ, Oral
Research
Typical Dose
0.005–0.1% in formulation
10 mg per day
Frequency
Once or twice daily
Daily for 10–30 days
Key Benefits
  • Stimulates collagen I and III synthesis in dermis
  • Reduces the appearance of fine lines and wrinkles
  • Improves skin elasticity and firmness
  • Inhibits collagenase (MMP-1) to preserve existing collagen
  • Enhances wound healing and skin repair
  • Well-tolerated in anti-aging serums and creams
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
Side Effects
  • Generally very well-tolerated
  • Rare skin irritation at very high concentrations
  • Possible formulation-dependent comedogenicity
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
Stacks With